When should chronic hepatitis C infection be treated?

When to Treat Hepatitis C

All patients with chronic hepatitis C infection should be treated, regardless of disease severity or fibrosis stage. The era of restricting treatment to those with advanced fibrosis is over—current direct-acting antivirals (DAAs) are highly effective, safe, and well-tolerated across all patient populations 1, 2.

Universal Treatment Recommendation

The fundamental principle is straightforward: every confirmed HCV infection represents an indication for antiviral treatment 3. This approach prioritizes:

• Preventing disease progression to cirrhosis, hepatocellular carcinoma, and liver-related death
• Reducing transmission to others
• Improving quality of life and extrahepatic manifestations
• Cost-effectiveness through early intervention rather than managing complications 4

Who Should Be Treated Immediately

High-Priority Patients (Treat Urgently)

Patients with progressive liver disease require urgent treatment 3:

• Advanced fibrosis (F3-F4/cirrhosis): FIB-4 score >3.25, transient elastography >12.5 kPa, or clinical evidence of cirrhosis (nodular liver, splenomegaly, platelets <150,000/mm³) 1
• Compensated cirrhosis (Child-Pugh A): Can be treated with standard pangenotypic regimens
• Decompensated cirrhosis: Requires specialized management but remains treatable with appropriate DAA selection 3
• Significant extrahepatic manifestations of HCV (cryoglobulinemia, glomerulonephritis)
• Post-liver transplant patients with HCV recurrence
• High risk of transmitting HCV: Healthcare workers, people who inject drugs, HIV-positive individuals, pregnant women planning conception

Standard Treatment Candidates

All other patients with detectable HCV RNA should be treated without delay 1, 2:

• No cirrhosis (F0-F2 fibrosis): Treatment is equally indicated regardless of minimal fibrosis 4
• Normal ALT levels: Do not exclude patients from treatment
• Minimal or no symptoms: Asymptomatic infection still warrants treatment
• Recently acquired infection: Treat after 8-12 weeks if no spontaneous clearance occurs 5

Simplified Treatment Eligibility

Treatment-naïve adults without cirrhosis can receive simplified treatment with minimal monitoring 1:

Eligible for Simplified Approach:

• No prior HCV treatment
• No cirrhosis (FIB-4 ≤3.25)
• No HIV or HBV coinfection
• eGFR ≥30 mL/min
• Not pregnant
• No hepatocellular carcinoma
• No prior liver transplant

Recommended Regimens (Simplified):

• Glecaprevir/pibrentasvir: 300/120 mg daily with food for 8 weeks 1
• Sofosbuvir/velpatasvir: 400/100 mg daily for 12 weeks 1

Patients Requiring Specialist Referral

While most patients can be treated in primary care settings, refer to hepatology/infectious disease specialists for:

• Decompensated cirrhosis (Child-Pugh B or C)
• Prior treatment failure with DAAs
• Severe renal impairment (eGFR <30 mL/min)
• HIV or HBV coinfection
• Hepatocellular carcinoma
• Post-liver transplant patients
• Complex drug-drug interactions that cannot be managed
• Pregnancy (treatment timing considerations)

Special Populations

Children

Children as young as 3 years old can now be treated with pangenotypic DAAs 2. Treatment should not be delayed in pediatric patients with confirmed chronic HCV.

Substance Use Disorder

Active or prior substance use disorder is NOT a contraindication to treatment 1, 6. However, these patients may require additional support for treatment adherence. Do not withhold treatment based on substance use history—this perpetuates health disparities and ongoing transmission.

Recently Acquired HCV

Treat after 8-12 weeks if spontaneous clearance has not occurred 5:

• In HIV-positive patients: If no 2-log HCV RNA drop at 4 weeks, spontaneous clearance is unlikely—proceed with treatment
• Use standard 8-12 week DAA regimens (not shortened courses)

Common Pitfalls to Avoid

1. Do not stage fibrosis as a prerequisite for treatment approval—this delays care and increases transmission 4
2. Do not withhold treatment from patients with substance use disorders—they have equal right to cure 6
3. Do not wait for ALT elevation—normal transaminases do not exclude significant disease 3
4. Do not delay treatment in young patients—early treatment prevents decades of disease progression 4
5. Do not require psychiatric clearance routinely—interferon-free regimens have minimal neuropsychiatric effects

Treatment Timing Algorithm

Immediate treatment (within 1-2 weeks):

• Decompensated cirrhosis
• Severe extrahepatic manifestations
• Post-transplant recurrence
• High transmission risk settings

Prompt treatment (within 1-3 months):

• Compensated cirrhosis (F4)
• Advanced fibrosis (F3)
• All other confirmed chronic HCV

The default answer is: treat now. There are virtually no scenarios where deferring treatment benefits the patient when effective, safe therapy is available.